Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides

• Published in: Drug delivery 2017-11, Vol.24 (1), p.1249-1261
• Main Authors: Farahmand, Leila, Darvishi, Behrad, Majidzadeh-A, Keivan
• Format: Article
• Language: English
• Subjects: decoy oligodeoxynucleotides; Humans; Inflammation; Inflammatory diseases; Nanomaterials; Nanostructures; NF-kappa B; NF-κB; Oligodeoxyribonucleotides; Review; Transcription factors
• ISSN: 1071-7544; 1521-0464
• DOI: 10.1080/10717544.2017.1370511

As a prototypical pro-inflammatory transcription factor, constitutive activation of NF-κB signaling pathway has been reported in several chronic inflammatory disorders including inflammatory bowel disease, cystic fibrosis, rheumatoid arthritis and cancer. Application of decoy oligodeoxynucleotides (ODNs) against NF-κB, as an effective molecular therapy approach, has brought about several promising outcomes in treatment of chronic inflammatory disorders. However, systematic administration of these genetic constructs is mostly hampered due to their instability, rapid degradation by nucleases and poor cellular uptake. Both chemical modification and application of delivery systems have shown to effectively overcome some of these limitations. Among different administered delivery systems, nanomaterials have gained much attention for delivering NF-κB decoy ODNs owing to their high loading capacity, targeted delivery and ease of synthesis. In this review, we highlight some of the most recently developed nanomaterial-based delivery systems for overcoming limitations associated with clinical application of these genetic constructs.